Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AZ Restructures, But Will Changes Sideline Plans To Accelerate R&D?

Executive Summary

AstraZeneca unveiled an R&D restructuring March 18 that will consolidate research to three locations and reduce headcount by 1,600, but the company will have to be dogged in its effort to relocate key employees if it is to ensure the changes don’t disrupt its broader goal of accelerating the pace of R&D.


Related Content

BioHub At Alderley Park: A Bioincubator With A Difference
Magnus Life Science Sets Up Five R&D-Centric Units At Top U.K. University
European Notebook: IPO Fever Comes To Europe; EMA Plans Adaptive Licensing Pilot Project
Glaxo’s Tres Cantos Open Lab Trawls For Answers To Neglected Diseases
AstraZeneca Seeking Patient Investors: Pipeline Holds Promise, But Long-Term
Better Late Than Never, J&J’s Innovation Centers Start Opening For Business
AstraZeneca’s Executive Shakeup Includes Global Strategist To Be Named Later
AZ Taps Outsider Soriot As CEO, While Roche Anoints 25-Year Veteran O'Day To Head Pharma Division
Pfizer Teams With Eight Boston-Area Research Institutions In $100MM Tie-Up


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts